Introduction {#s0005}
============

Despite the heterogeneity of breast cancer (BC), global analyses of tumors using genetic profiles have identified gene expression signatures that characterize many intrinsic tumor subtypes with different biology and clinical behavior. In particular, the role of hormone status is important to define the prognosis and to predict the response to therapy for BC patients. Currently, hormone receptors are widely used as prognostic and predictive factors to manage decision-making in BC patients. Estrogen receptor (ER) expression is mostly important because it can predict about 50--70% of tumor responses under treatment with anti-estrogens, whereas response rate is less than 10% in ER-negative BCs and perhaps 0% in truly ER-absent cases [@bb0005], [@bb0010], [@bb0015], [@bb0020]. Levels of ER affect the time-distribution of BC relapses, ER positivity being associated with more delayed recurrences compared to ER absence [@bb0025].

Androgens seem also to have importance in female BC patients. BC risk appears higher in postmenopausal women when both estrogen and androgen levels are increased [@bb0030], [@bb0035], [@bb0040]. Up to now, how androgen function can favor BC risk is not well known. Some studies showed an effect of androgens on proliferation of breast tissue [@bb0045], [@bb0050], [@bb0055]. Androgen receptor (AR) has recently been reported to have both an oncogenic and tumor suppressive role. Some studies reported that AR expression is quite elevated in most ER-positive tumors but less in ER-negative tumors [@bb0060], [@bb0065], [@bb0070], [@bb0075], [@bb0080]. These data are still controversial because the same authors described a role of AR status in predicting response rate and overall survival under hormonal therapy, and at the same time they found no association between AR expression and disease-free survival in ER-positive tumors. In the same works ER status maintained the predominant role as independent prognostic factor for disease-free survival [@bb0065], [@bb0070], [@bb0075]. For some authors, AR expression was related to a better survival when it was co-expressed with ER, [@bb0080] but not for others [@bb0085]. The availability of anti-androgen compounds (i.e., bicalutamide, enzalutamide) opened new perspectives for the treatment of advanced BC expressing AR. To select patients suitable for this kind of treatment, it is necessary to assess AR in tumor tissue. Often only primary tumor samples are available, but not metastatic samples. When we assess AR expression in the primary sample, is it important to assess its expression in metastatic tissue as well?

The concordance of AR expression between primary and metastatic samples is not well defined. Moreover the time elapsed between the biopsy of the primary tumor and the biopsy of a metastasis could affect the degree of change in AR expression between the two samples. This difference could make difficult the decision-making process for anti-androgen therapy. The purpose of this study is the analysis of AR expression in formalin-fixed, paraffin-embedded (FFPE) primary tumors and metastases, and the assessment of changes in AR expression levels over time.

Materials and Methods {#s0010}
=====================

Patients and Sample Selection {#s0015}
-----------------------------

This retrospective study was carried out on a case series of patients enrolled from 2000 to 2008 in clinical or biological studies performed at our Institute in collaboration with the Cancer Prevention Unit and the Breast Surgery Unit of Morgagni-Pierantoni Hospital in Forlì. Patients aged ≥18 years with a histological diagnosis of invasive BC were eligible. All the patients had to be followed up for at least 5 years, unless they had relapsed earlier. The study protocol was reviewed and approved by the IRST and AVR (Area Vasta Romagna) Ethics Committee (approval no.3692) and patients provided written informed consent according to Italian privacy law. The original hematoxylin and eosin stained sections were reviewed by the pathologist in order to select the most representative inclusion of tumor tissue for each patient.

Biomarker Determination {#s0020}
-----------------------

Tumor material obtained during surgery was fixed in neutral buffered formalin and embedded in paraffin. Four-micron sections were mounted on positive-charged slides for each patient (Bio Optica, Milan, Italy). Biomarker determinations were performed according to European Quality Assurance guidelines. Immunostaining for conventional biomarkers and AR expression was performed using the Ventana Benchmark^XT^ staining system (Ventana Medical Systems, Tucson, AZ, USA) with the Optiview DAB Detection Kit (Ventana Medical Systems). ER, PgR, Ki67 (Leica, Novocastra, Newcastle, UK), HER2 (Dako, Carpinteria, CA, USA) and AR (SP107 Cell Marque, Ventana Medical Systems) antibodies were used. For ER, PgR, Ki67 and HER2 detection, tissue sections were incubated for 60 minutes with antibodies diluted 1:80, 1:40, 1:100 and 1:350, respectively, in antibody diluents (Ventana Medical Systems). AR antibody, pre-diluted by the supplier, was used. Sections were incubated for 16 minutes and automatically counterstained with hematoxylin II (Ventana Medical Systems). Biomarker positivity was detected and semiquantitatively quantified as the percentage ratio between immunopositive tumor cells and the total number of tumor cells. All samples were evaluated by 2 independent observers and any disagreement (\>10% of positive cells for the different markers) was resolved by consensus after joint review using a multihead microscope.

Molecular subtypes were defined by the detection of ER, PgR, Ki67 and HER2. ER-positivity and PgR-positivity were considered as ≥1% tumor cells staining for ER and PgR, respectively; Ki67 was considered high when detected in ≥20% of tumor cells; HER2-positivity was defined as 3+ staining intensity by IHC or as HER2 amplification (HER2/Chromosome 17 centromere ratio ≥2.0, or mean HER2 gene copy number ≥6 per tumor cell). The expression of these biomarkers allowed to classify samples according to the St. Gallen expert consensus and the ASCO-CAP guidelines [@bb0090], [@bb0095]. Luminal A-like (ER-positive, PgR ≥ 20%, low Ki67 (\<20%), HER2-negative), luminal B-like (ER-positive, PgR \<20%, high Ki67 (≥20%), HER2-positive or HER2-negative), HER2-positive non-luminal (ER-negative, PgR-negative, HER2-positive), and triple-negative (ER-negative, PgR-negative, HER2-negative).

As regards AR expression, we chose two different cut off values ≥1% and ≥10% of immunopositive tumor cells to assess AR positivity. Staining intensity (i.e., 0, 1+, 2+, 3+) was also analyzed in order to calculate the H-score, defined as the product of the percentage of AR-positive tumor cells and staining intensity.

Statistical Analyses {#s0025}
--------------------

All the data were summarized using descriptive statistics. Concordance of AR expression was defined as either positive or negative in both tumor and metastasis, while discordance was defined as positivity at one site and negativity at the other or *vice versa*. The concordance rate was calculated as the proportion of concordant cases with respect to the total number of patients. The two-sided exact binomial 95% confidence interval (95% CI) was estimated. McNemar\'s test was performed in order to compare AR status between the primary tumor and paired metastatic sites.

Univariable linear regression was used to assess and graphically display the relationship between the time elapsed from the removal of the primary tumor to sampling of the metastasis and the difference of AR expression between the two samples.

All statistical analyses were carried out using SAS software, version 9.4 (SAS Institute, Cary, NC, USA).

Results {#s0030}
=======

Two hundred fourteen patients meeting eligibility criteria were included in the study ([Figure 1](#f0005){ref-type="fig"}). Primary breast cancer archival tissue was available for 164 patients, 154 of whom had complete tumor characterization (expression of ER, PgR, Ki67, and HER2 status) and established BC subtype. Eighty-three patients had tissue samples from a metastasis, and 79 of them had the molecular subtype determined. For 33 patients both primary and metastatic tumor tissues were available. All patients\' characteristics are reported in [Table 1](#t0005){ref-type="table"}. Forty (19.1%) had metastatic disease at diagnosis. The median age was 58 years (range: 26--86). Tumor biological characteristics are reported in [Table 2](#t0010){ref-type="table"}.Figure 1Consort diagram of the study.Figure 1Table 1Patient\'s CharacteristicsTable 1All Patients, as Per Clinical Practice[\*](#tf0005){ref-type="table-fn"}\
(n = 214)N. (%)Available specimen Primary tumor164 (76.6) Metastasis83 (34.4) Both primary and metastasis33 (15.4)Age (years): median value (range)58 (26--86)Adjuvant chemotherapy No64 (36.8) Yes110 (63.2) Unknown40Adjuvant endocrine therapy No67 (38.5) Yes107 (61.5) Unknown40Histotype Ductal169 (82.4) Lobular28 (13.7) Other8 (3.9) Unknown9Tumor stage 190 (49.2) 270 (38.3) 37 (3.8) 416 (8.7) Unknown31Nodal involvement 072 (40.0) 171 (39.5) 220 (11.1) 317 (9.4) Unknown34Metastases at diagnosis Yes40 (19.1) No169 (80.9) Unknown51st-line endocrine therapy for advanced BC Letrozole72 (46.5) Anastrozole32 (20.6) Exemestane39 (25.2) Tamoxifen9 (5.8) Fulvestrant3 (1.9) Unknown59[^2]Table 2Tumor biological CharacteristicsTable 2Primary Tumor\
(n = 164)Metastases\
(n = 83)As Per Clinical Practice[\*](#tf0010){ref-type="table-fn"}\
(n = 214)N. (%)N. (%)N. (%)Grade 16 (4.6)06 (3.7) 249 (38.0)11 (47.8)67 (40.8) 374 (57.4)12 (52.2)91 (55.5) Unknown356050ER status \<1%30 (18.7)8 (9.8)33 (15.4) ≥1%130 (81.3)74 (90.2)181 (84.6) Unknown410PgR status \<1%49 (30.6)30 (36.6)75 (35.0) ≥1%111 (69.4)52 (63.4)139 (65.0) Unknown410 \<20%81 (50.6)41 (50.0)113 (52.8) ≥20%79 (49.4)41 (50.0)101 (47.2) Unknown410Ki67 status \<20%75 (47.8)48 (62.3)113 (53.6) ≥20%82 (52.2)29 (37.7)98 (46.4) Unknown763HER2 status Negative100 (63.7)71 (88.7)152 (71.4) Positive57 (36.3)9 (11.3)61 (28.6) Unknown731AR status \<1%28 (17.1)22 (26.5)46 (21.5) ≥1%136 (82.9)61 (73.5)168 (78.5) Unknown000 \<10%33 (20.1)33 (39.8)62 (29.0) ≥10%131 (79.9)50 (60.2)152 (71.0)[^3]

Among the 164 primary tumor samples, 136 (82.9%) were AR positive ([Figure 2](#f0010){ref-type="fig"}) according to a cut off value of ≥1%, and 131 (79.9%) with the cut-off value of ≥10% ([Table 2](#t0010){ref-type="table"}). Similar data were obtained for metastases: on a total of 83 metastases analyzed, 61 (73.5%) were AR positive according to a cut off value ≥1%, and 50 (60.2%) by using ≥10% cut off value ([Table 2](#t0010){ref-type="table"}). AR H-score median value was 240 (range 0--300) in primary tumors and 210 in metastases (range 0--300). AR expression was higher in luminal A and luminal B tumors than in HER2-positive and triple negative tumors, both on primary tumors ([Table 3A](#t0015){ref-type="table"}) and metastases ([Table 3B](#t0020){ref-type="table"}).Figure 2Ductal infiltrating carcinomas of the breast showing negativity for AR expression (A), a moderate and heterogeneous (2+) AR nuclear positivity (B), and a strong and homogeneous (3+) AR nuclear positivity (C). All 10× magnification.Figure 2Table 3ADistribution of AR Expression in the Different Primary Tumor SubtypesTable 3APrimary Tumor Subtypes (N. = 154)LA[\*](#tf0015){ref-type="table-fn"}LB[\#](#tf0020){ref-type="table-fn"}LB-HER2+[\*\*](#tf0025){ref-type="table-fn"}TN[\^](#tf0030){ref-type="table-fn"}HER2+ (HR-)[@](#tf0035){ref-type="table-fn"}N. (%)N. (%)N. (%)N. (%)N. (%)Primary tumor AR negative (\<1%)3 (9.4)8 (14.5)7 (17.9)5 (50.0)5 (27.8) AR positive (≥1%)29 (90.6)47 (85.5)32 (82.1)5 (50.0)13 (72.2) AR negative (\<10%)4 (12.5)8 (14.5)9 (23.1)6 (60.0)7 (38.9) AR positive (≥10%)28 (87.5)47 (85.5)30 (76.9)4 (40.0)11 (61.1)[^4][^5][^6][^7][^8]Table 3BDistribution of AR Expression in the Different tumor Subtypes on MetastasesTable 3BTumor Subtype on Metastases (N. = 79)LA[\*](#tf0040){ref-type="table-fn"}LB[\#](#tf0045){ref-type="table-fn"}LB-HER2+[\*\*](#tf0050){ref-type="table-fn"}TN[\^](#tf0055){ref-type="table-fn"}HER2+ (HR-)[@](#tf0060){ref-type="table-fn"}N. (%)N. (%)N. (%)N. (%)N. (%)Metastasis AR negative (\<1%)2 (12.5)12 (25.5)2 (25.0)4 (57.1)1 (100) AR positive (≥1%)14 (87.5)35 (74.5)6 (75.0)3 (42.9)0 AR negative (\<10%)4 (25.0)17 (36.2)4 (50.0)6 (85.7)1 (100) AR positive (≥10%)12 (75.0)30 (63.8)4 (50.0)1 (14.3)0[^9][^10][^11][^12][^13]

The characteristics of patients for whom samples for both primary tumor and metastasis were evaluable are reported in [Table 4](#t0025){ref-type="table"}. Tumor biological characteristics for the same group are reported in [Table 5](#t0030){ref-type="table"}. The concordance between AR-positivity in primary tumor and metastasis was 66.7% (95% CI 50.6--82.8; *P* = .035) by using 1% as cut off value, and it dropped to 60.6% (95% CI 43.9--77.3; *P* = .002) by using the cut off value of 10% ([Table 6](#t0035){ref-type="table"}).Table 4Characteristics of Patients for Whom Samples of Both Primary Tumor and Metastasis were AvailableTable 4No. (%)Median age, years (range)55 (33--76)Adjuvant chemotherapy No10 (33.3) Yes20 (66.7) Unknown3Adjuvant endocrine therapy No8 (26.7) Yes22 (73.3) Unknown3Histotype Ductal23 (71.9) Lobular6 (18.7) Other3 (9.4) Unknown1Tumor stage 114 (48.3) 214 (48.3) 30 41 (3.4) Unknown4Nodal involvement 013 (44.8) 111 (37.9) 25 (17.3) 30 Unknown4Metastases at diagnosis Yes3 (9.4) No29 (90.6) Unknown1First-line endocrine therapy for advanced breast cancer Letrozole8 (27.6) Anastrozole10 (34.5) Exemestane8 (27.6) Tamoxifen3 (10.3) Fulvestrant0 Unknown4Table 5Tumor Biological Characteristics of Patients for Whom Samples of Both Primary Tumor and Metastasis were AvailableTable 5Primary Tumor\
(n = 33)Metastasis\
(n = 33)No. (%)No. (%)Grade 11 (4.5)0 28 (36.4)5 (50.0) 313 (59.1)5 (50.0) Unknown1123ER status \<1%5 (17.2)4 (12.5) ≥1%24 (82.8)28 (87.5) Unknown41PgR status \<1%7 (24.1)18 (56.2) ≥1%22 (75.9)14 (43.8) Unknown41 \<20%13 (44.8)18 (58.1) ≥20%16 (55.2)13 (41.9) Unknown42Ki67 status \<20%12 (41.4)18 (58.1) ≥20%17 (58.6)13 (41.9) Unknown42HER2 status Negative23 (85.2)28 (90.3) Positive4 (14.8)3 (9.7) Unknown62AR status \<1%4 (12.1)11 (33.3) ≥1%29 (87.9)22 (66.7) Unknown00 \<104 (12.1)15 (45.5) ≥1029 (87.9)18 (54.5)[^14]Table 6Concordance Between AR Evaluated in Primary Tumor and in MetastasisTable 6MetastasisNegativePositiveTotalMcNemar TestNo. (%)No. (%)No. (%)pPrimary tumor AR negative (\<1%)2 (50.0)2 (50.0)4 (12.1) AR positive (≥1%)9 (31.0)20 (69.0)29 (87.9)Concordance: 66.7%\
(95% CI 50.6--82.8)\
0.035 AR negative (\<10%)3 (75.0)1 (25.0)4 (12.1) AR positive (≥10%)12 (41.4)17 (58.6)29 (87.9)Concordance: 60.6%\
(95% CI 43.9--77.3)\
0.002[^15]

We used univariable linear regression to study the association between the time elapsed from the removal of the primary tumor to the metastasis biopsy (months; x-axis) and the changes in AR expression between the two samples (absolute variation in the percentage of AR-positive cells between the two samples, y-axis). No association between time and AR expression was observed (R-squared = 0.04 and adjusted R-squared = 0.0091, *P* = .264) ([Figure 3](#f0015){ref-type="fig"}).Figure 3Univariable linear regression to assess the association between the time elapsed from the removal of the primary tumor to the metastatic biopsy (months; x-axis) and the changes in AR expression between the two samples (absolute variation in the percentage of AR-positive cells between the two samples, y-axis).Figure 3

Discussion {#s0035}
==========

Collins and colleagues reported that AR is most commonly expressed in luminal A and B invasive BC and it is present in approximately one-third of basal-like cancers [@bb0100].

Our results are in agreement with these findings because in our case series AR is more frequently expressed in luminal than the other subtypes, both in primary tumors and metastases. Nonetheless, the low number of HER2-positive and triple negative BC in our study precludes firm conclusions about the distribution of AR expression in different molecular subtypes. Despite the increasing use of gene expression profiles, such as Oncotype Dx or PAM50, we classified tumors according to a conventional immunohistochemistry marker panel (hormone receptors, HER2 and Ki67 expression). We opted for the latter because it has been seen that molecular assays do not furnish superior prognostic information to that of tumor morphology and immunohistochemistry [@bb0105], [@bb0110].

Only a few articles have been published on the comparison of AR expression evaluated on primary tumor and metastasis [@bb0115], [@bb0120]. We found a statistically significant concordance between AR expression in primary tumor and metastasis using two cut off values (1% and 10%). Due to the retrospective nature and potential selection bias of our study, we did not evaluate the prognostic or predictive role of AR expression in these two types of specimens.

Some authors observed that hormone receptor status (ER and PgR) may change several times over the course of the disease. These changes could be associated with prognostic worsening. Hence, they suggest repeating the hormone receptor determination in metastatic BC patients [@bb0125]. For this reason we assessed the association between the time-interval from primary tumor removal to biopsy of the metastatic site, and the change in AR expression between the two samples. We found that the variation in the sampling time of the two types of specimens does not explain the difference of AR expression between primary and metastatic lesions, because R-squared value of a linear regression of time to AR change is close to 0. This finding might reflect the high spatiotemporal variability of AR expression, with intratumor spatial heterogeneity exceeding temporal heterogeneity.

Conclusions {#s0040}
===========

Although our results must be interpreted cautiously due to the low number of paired primary tumor and metastasis samples analyzed, they nevertheless suggest that the evaluation of AR by IHC should be performed in all biological material available for each patient, regardless of the time interval between samplings, to plan an anti-AR therapeutic approach.

[^1]: These authors equally contributed to this work.

[^2]: Clinical practice: biomarker expression measured in metastases (when a biopsy was performed on metastases) or in primary tumors (when biopsy on metastases had not been performed).

[^3]: Clinical practice: biomarker expression measured in metastases (when a biopsy was performed on metastases) or in primary tumors (when biopsy on metastases had not been performed).

[^4]: LA, luminal A-like: ER+, PgR ≥20%, Ki67\< 20%, HER2−;

[^5]: LB, luminal B-like: ER+, PgR \<20% or Ki67 ≥ 20%, HER2−;

[^6]: LB-HER2+, luminal B-like HER2-positive: ER+, PgR \<20% or Ki67 ≥ 20%, HER2+;

[^7]: TN, triple-negative: ER−, PgR−, HER2−;

[^8]: HER2+ (HR−), HER2-positive, hormone receptor-negative: ER−, PgR−, HER2+.

[^9]: LA, luminal A-like: ER+, PgR ≥20%, Ki67\< 20%, HER2−;

[^10]: LB, luminal B-like: ER+, PgR \<20% or Ki67 ≥ 20%, HER2−;

[^11]: LB-HER2+, luminal B-like HER2-positive: ER+, PgR \<20% or Ki67 ≥ 20%, HER2+;

[^12]: TN, triple-negative: ER−, PgR−, HER2−;

[^13]: HER2+ (HR−), HER2-positive, hormone receptor-negative: ER−, PgR−, HER2 + .

[^14]: ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor 2; AR, androgen receptor.

[^15]: CI, confidence interval.
